1Reinfuss M, Stelmach A, Mitus J, et al. Typical medullary carcinoma of the breast: a clinical and pathological analysis of 52 cases. J Surg Oncol ,1995,60: 89-94.
2Pedersen L, Zedeler K, Holck S, et al. Medullary carcinoma of the breast:prevalence and prognostic importance of classical risk factors in breast cancer. Eur J Cancer, 1995, 31: 2289-2295.
4Thurman SA, Schnitt SJ, Connolly JL, et al. Outcome after breast-conserving therapy for patients with stage Ⅰ or Ⅱ mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys, 2004, 59: 152-159.
5Perkins GH, Green MC, Middleton LP, et al. Medullary breast carcinoma: outcomes and prognosis with the utilization of chemotherapy. J Clin Oncol, 2004, 22: 671.
6Jensen ML, Kiaer H, Andersen J, et al. Prognostic comparison of three classifications for medullary carcinomas of the breast. Histopathology, 1997,30:523-532.
7Cremoux PD, Salomon AV, Liva S, et al. P53 mutation as a genetic trait of typical medullary breast carcinoma. J Natl Cancer Inst, 1999, 91: 641-643.
8Xu R, Feiner H, Li P, et al. Differential amplification and overexpression of HER-2/neu, p53, MIB1, and estrogen receptor/progesterone receptor among medullary carcinoma, atypical medullary carcinoma, and high-grade invasive ductal carcinoma of breast. Arch Pathol Lab Med, 2003, 127: 1458-1464.
9Cance WG,Careg LA,Calvo BF,et al.Long term outcome of neoadjuvant therapy for locally advanced breast preservation and predicts outstanding local control and survival[].Annals of Surgery.2002
10Fazeny-Dorner B,Piribauer M,Wenzel C,et al.Cytogenetic and comparative genomic hybridization findings in four cases of breast cancer after neoadjuvant chemotherapy[].Cancer Genetics and Cytogenetics.2003
